Intranasal ketamine for acute cluster headache attacks-Results from a proof-of-concept open-label trial.
Anja Sofie PetersenAdam S PedersenMads Christian J BarloesePer HolmOle PedersenRigmor H JensenAgneta H SnoerPublished in: Headache (2021)
Intranasal ketamine may be an effective acute treatment for CH at 30 min but should be tested in a larger controlled design. Patients and physicians should be conscious of the abuse potential of ketamine.
Keyphrases
- liver failure
- open label
- pain management
- end stage renal disease
- respiratory failure
- clinical trial
- phase ii
- study protocol
- phase iii
- newly diagnosed
- ejection fraction
- primary care
- drug induced
- aortic dissection
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- squamous cell carcinoma
- room temperature
- hepatitis b virus
- intensive care unit
- risk assessment
- extracorporeal membrane oxygenation
- smoking cessation
- ionic liquid